Sign in
Taking peopleNo phase

Intradermal Exosomes, Platelet-Rich Plasma, and Steroids for Post-Herpetic Neuralgia

Key facts

Who runs it
Zagazig University
Where
Egypt1 site in 1 countryChoose a country to see its sites
Trial code
Status
Recruiting
People taking part
45 people, planned
Started
2 Feb 2025
Planned end
11 Nov 2026
Type of study
Interventional, 3 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • Exosomes
  • PRP
  • Corticosteroids
Record updated
4 May 2026

Who can take part

Age
18 years and older
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 2 criteriaShow less

Who can take part

  • Patients with post-herpes zoster persistent dermatomal pain consistent with post-herpetic neuralgia for at least 90 days; Male or female patients. Age 18 years or older. Willingness to comply with study procedures and attend follow-up visits. Ability and willingness to provide written informed consent

Who cannot take part

  • History of hypersensitivity to any of the study treatments. Pregnancy. Any type of skin infection involving the affected dermatome. Immunocompromised patients, including patients with cancer or HIV. Patients with bone marrow aplasia. Patients with known bleeding tendency, platelet dysfunction, or thrombocytopenia, defined as platelet count less than 150 × 10⁹/L; Regular use of anticoagulant or antiplatelet drugs

This trial has no sites in United States.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

This randomized controlled clinical trial will evaluate and compare the efficacy and safety of intradermal injection of exosomes, platelet-rich plasma, and corticosteroid in patients with post-herpetic neuralgia. Forty-five adult patients with dermatomal pain persisting for at least 90 days after herpes zoster will be enrolled from outpatient clinics. Participants will be assigned to one of three groups: intradermal exosome injection, intradermal autologous platelet-rich plasma injection, or intradermal triamcinolone acetonide injection. Each group will receive four treatment sessions every two weeks. Outcomes will include pain severity, neuropathic pain characteristics, quality of life, patient satisfaction, and adverse effects, assessed at baseline, at the final session, and during follow-up visits at 3 and 6 months after the last session.

The 3 groups in the trial

  • ExosomesTreatment being tested

    Participants will receive intradermal injections of exosome product into the affected dermatome. The dermatome will be marked and divided into 1 cm² squares, and 0.1 cc will be injected intradermally into each square using an insulin syringe. Treatment will be given every two weeks for a total of four sessions, followed by visits at 3 and 6 months after the last session.

  • PRPTreatment being tested

    Participants will receive intradermal injections of autologous platelet-rich plasma into the affected dermatome. Ten mL of blood will be collected under aseptic conditions and centrifuged at 1000 rpm for 10 minutes. The lower 1-2 cc of plasma will be used as platelet-rich plasma concentrate. The affected dermatome will be marked into 1 cm² squares, and 0.1 cc PRP will be injected intradermally into each square. Treatment will be given every two weeks for four sessions, followed by visits at 3 and 6 months after the last session.

  • CorticosteroidsExisting treatment, for comparison

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
A Comparative Study of Intradermal Injection of Exosomes, Platelet-Rich Plasma and Steroids in the Treatment of Post-Herpetic Neuralgia
Record updated
4 May 2026